Skip to main content

Asana is valued at $5.5 billion after direct listing debut

Workplace management software maker Asana attained a market value of about $5.5 billion after a direct listing, one of two Wednesday to go public via the initial public offering alternative.

Shares of San Francisco-based Asana, which didn’t sell any shares, opened trading in New York at $27 apiece and closed up 6.7% from that price at $28.80 a share. The $5.5 billion valuation is based on a fully diluted share count.

Palantir Technologies, the data-mining company founded by billionaire Peter Thiel, also went public via a direct listing on Wednesday, with its shares falling 5% from its opening price to $9.50 a share. Only two major companies had previously gone public through direct listings, Spotify Technology SA in 2018 and Slack Technologies Inc. last year.

Asana, whose founders include Facebook co-founder Dustin Moskovitz, was valued at $1.5 billion in a 2018 funding round led by Al Gore’s Generation Investment Management. More recently, it has fetched a valuation of about $5 billion on the secondary market, Bloomberg has reported. It has also received funding from Thiel’s Founders Funds, according to the company’s filings.

‘Democratic Process’

Moskovitz, Asana’s chief executive officer, said the company, which didn’t need to raise money, was attracted to the “efficient pricing” of a direct listing.

“We thought it’s a more fair, democratic process for employees and shareholders to have the opportunity for liquidity at the same time,” he said in an interview.

Moskovitz added that Asana hasn’t done any acquisitions and doesn’t see that changing.

About 40% of Asana’s revenue comes from outside the U.S. and it’s present in 190 countries, its executives said during the presentation. It has a gross margin of 87% in the first half, similar to 86% in the last fiscal year.Loss Grows

The company reported $99.7 million in revenue for the six months ended July 31, compared with $61.1 million for the same period last year. Its net loss more than doubled in that period to $76.9 million as research, sales and marketing costs shot up.

The New York Stock Exchange had set a reference price of $21 a share for the stock. Unlike the offer price in a traditional IPO, no shares changed hands at the reference price, which is intended only as a guide for investors and is needed for the stock to begin trading on the exchange.

Asana’s shares are trading under the symbol ASAN. While banks don’t underwrite shares as they do in a traditional IPO, they do serve as advisers in a direct listing. Morgan Stanley served as Asana’s lead adviser. JPMorgan Chase & Co., Credit Suisse Group AG and Jefferies Financial Group Inc. also advised Asana.

More must-read tech coverage from Fortune:



from Fortune https://ift.tt/2EMmqmM
Labels:

Comments

Post a Comment

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $
Post a Comment
Read more

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be
Post a Comment
Read more